Cantargia enters into agreement with Patheon Biologics BV for antibody CAN04 production.

NORDIC BUSINESS REPORT-May 14, 2019-Cantargia enters into agreement with Patheon Biologics BV for antibody CAN04 production

(C)2019 M2 COMMUNICATIONS http://www.m2.com

Cantargia AB (STO:CANTA), a biotechnology company that develops antibody-based treatments for life-threatening diseases, announced on Monday the signing of an agreement with Patheon Biologics BV, a part of ThermoFischer Scientific (NYSE:TMO), regarding the future production of the antibody CAN04 (nidanilimab).

Currently, CAN04 is in phase IIa clinical development for non-small cell lung cancer and pancreatic cancer. In order to prepare for late stage clinical trials, increased production capacity is part of the development plan.

With this agreement, Cantargia secures additional production capacity for future...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT